Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

French To Press On With Rapid Trial Approval System

Pilot Experience With ATMPs Still To Be Evaluated

Executive Summary

A French pilot intended to speed up the authorization of clinical trials is to be continued after a pilot phase showed it was working well.

You may also be interested in...



Long-Awaited EU Clinical Trials Portal Meets Major Milestone

A simplified process for registering and evaluating clinical trials promised by the EU Clinical Trial Regulation is finally set to become a reality.

France Invites Advanced Therapy Makers To Use Fast-Track Trial Approval Pathway

Updated guidance on France’s experimental fast-track procedure for approving clinical trials shows that the pathway has entered a new phase.

Denmark Planning To Impose Drug Stockpiling Obligations From July

A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS141051

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel